2,2'-((2-(5-bromo-2-hydroxyphenyl)-5-nitro-1H-benzo[d]imidazole-1,3(2H) diyl)bis(methylene))bis(4-bromophenol) | 1585984-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2,2'-((2-(5-bromo-2-hydroxyphenyl)-5-nitro-1H-benzo[d]imidazole-1,3(2H) diyl)bis(methylene))bis(4-bromophenol)
• 英文别名: 4-bromo-2-[[2-(5-bromo-2-hydroxyphenyl)-3-[(5-bromo-2-hydroxyphenyl)methyl]-5-nitro-2H-benzimidazol-1-yl]methyl]phenol
• CAS: 1585984-51-5
• 化学式: C₂₇H₂₀Br₃N₃O₅
• 分子量: 706.185
• InChiKey: DRJFKAQEUALKDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-硝基邻苯二胺 、 5-溴水杨醛 在 三甲基氯硅烷 作用下， 以 乙醇 、 水 为溶剂， 以82%的产率得到2,2'-((2-(5-bromo-2-hydroxyphenyl)-5-nitro-1H-benzo[d]imidazole-1,3(2H) diyl)bis(methylene))bis(4-bromophenol)
  参考文献：
  名称：

  Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer's disease

  摘要：

  Amyloid-beta (A beta), a neurotoxic peptide, is linked to the onset of Alzheimer's disease (AD). Increased A beta content within neuronal cell mitochondria is a pathological feature in both human and mouse models with AD. This accumulation of A beta within the mitochondrial landscape perpetuates increased free radical production and activation of the apoptotic pathway. Human Presequence Protease (hPreP) is responsible for the degradation of mitochondrial amyloid-beta peptide in human neuronal cells, and is thus an attractive target to increase the proteolysis of A beta. Therefore, it offers a potential target for Alzheimer's drug design, by identifying potential activators of hPreP. We applied structure-based drug design, combined with experimental methodologies to investigate the ability of various compounds to enhance hPreP proteolytic activity. Compounds 3c & 24c enhanced hPreP-mediated proteolysis of A beta (1-42), pF(1)beta (2-54) and fluorogenic-substrate V. These results suggest that activation of hPreP by small benzimidazole derivatives provide a promising avenue for AD treatment. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2014.02.046

文献信息

• Identification of human presequence protease (hPreP) agonists for the treatment of Alzheimer's disease
  作者：Jhansi Rani Vangavaragu、Koteswara Rao Valasani、Xueqi Gan、Shirley ShiDu Yan

  DOI：10.1016/j.ejmech.2014.02.046

  日期：2014.4

  Amyloid-beta (A beta), a neurotoxic peptide, is linked to the onset of Alzheimer's disease (AD). Increased A beta content within neuronal cell mitochondria is a pathological feature in both human and mouse models with AD. This accumulation of A beta within the mitochondrial landscape perpetuates increased free radical production and activation of the apoptotic pathway. Human Presequence Protease (hPreP) is responsible for the degradation of mitochondrial amyloid-beta peptide in human neuronal cells, and is thus an attractive target to increase the proteolysis of A beta. Therefore, it offers a potential target for Alzheimer's drug design, by identifying potential activators of hPreP. We applied structure-based drug design, combined with experimental methodologies to investigate the ability of various compounds to enhance hPreP proteolytic activity. Compounds 3c & 24c enhanced hPreP-mediated proteolysis of A beta (1-42), pF(1)beta (2-54) and fluorogenic-substrate V. These results suggest that activation of hPreP by small benzimidazole derivatives provide a promising avenue for AD treatment. Published by Elsevier Masson SAS.